(1) Walsmann, P. et al. (1972) Acta biol. med. germ. 28, 577-585
Inactivation of Trypsin and Thrombin through 4-Amidinobenzene sulfonyl fluoride and 4-(2-Aminoethyl)-benzene sulfonyl fluoride.
(2) Markwardt, F. et al. (1973) Thrombosis Res. 2, 343-348
Synthetic low molecular weight inhibitors of serum kallikrein.
(3) Murphy,. B.J. et al. (1993) J. Biol. Chem. 268, 27355-27362
Identification of the sites of selective phosphorylation and dephosphorylation of the rat brain Na+ channel a subunit by cAMP-dependent protein kinase and phosphoprotein phosphatases.
(4) Nathan, D.F. & Lindquist. S. (1995) Mol. Cell. Biol. 15, 3917-3925
Mutational analysis of HSP90 function: Interactions with a steroid receptor and a protein kinase.
(5) Taylor, J.A. et al. (1995) Mol. Cell. Biol. 15, 4149-4157
Activation of the high-affinity immunoglobulin E receptor FceRI in RBL-2H3 cells is inhibited by syk SH2 domains.
(6) Taylor, J.A. et al. (1995) Immunology 86, 629-635
Serine protease inhibitors block the priming of monocytes for enhanced superoxide release.
AEBSF irreversibly inactivates thrombin and other serine proteases (e. g. chymotrypsin, kallikrein, plasmin, proteinase K, trypsin) by sulfonylation of a functional group in the active center of the enzyme (1, 2). AEBSF (LD50 oral, mouse 2.8 g/kg) is a substantially less toxic substitute for PMSF and DFP. It is higly water-soluble and its solutions have an acidic pH. At this pH, stability is high. AEBSF is inactivated at 37°C by 50 % after 5 hours. We recommend storage of the stock solution (e. g. 20 mM or 100 mM in water or buffer) at -20°C (stable for up to 2 months; at +4°C approx. 1 week; ref. 6). It should be added to the assay buffers just before use at a final concentration of 0.1 - 2 mM (e. g. ref. 3-5).